Related Experiment Videos
Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections
1Department of Internal Medicine, First University Faculty of Medicine, Elaziö, Turkey.
Insights
Octreotide treatment significantly improved symptoms and reduced heart muscle thickness in patients with primary hypertrophic cardiomyopathy. This four-week study showed promising results with no observed side effects.
Area of Science:
- Cardiology
- Endocrinology
Background:
- Primary hypertrophic cardiomyopathy is linked to growth factors.
- Octreotide, a somatostatin analogue, mitigates growth factor effects and reduces left ventricular mass in acromegaly patients.
Observation:
- Three primary hypertrophic cardiomyopathy patients received subcutaneous octreotide for four weeks.
- Patients' functional class improved from NYHA class II/III to class I.
Findings:
- Significant reductions in left ventricular posterior wall thickness, interventricular septum thickness, and overall left ventricular mass were observed.
- Left ventricular end-diastolic and end-systolic diameters increased.
- Two patients exhibited improved diastolic filling and normalized hyperdynamic systolic performance.
- No adverse events were reported during octreotide administration.
Implications:
- Short-term octreotide treatment shows potential as a therapeutic option for primary hypertrophic cardiomyopathy.
- Further research is warranted to explore the long-term efficacy and safety of octreotide in hypertrophic cardiomyopathy management.
Abstract:
Growth factors have been shown to be associated with primary hypertrophic cardiomyopathy. Octreotide, a long acting somatostatin analogue, can prevent the stimulating effect of growth factors and decrease the left ventricular mass in patients with acromegaly. In the light of these results, three patients with primary hypertrophic cardiomyopathy were treated with subcutaneous octreotide (50 micrograms three times a day during the first week and 100 micrograms twice a day for the following three weeks). Initially, two patients were in New York Heart Association class II in and one was in class III. At the end of a four week treatment session all were in class I. There were significant decreases in left ventricular posterior wall thickness, interventricular septum thickness, and left ventricular mass in all three patients. Both left ventricular end diastolic and end systolic diameters had increased in all of the patients at the end of the fourth week. Two of three patients showed improved diastolic filling: their hyperdynamic systolic performance returned to normal. No side effects were observed during octreotide treatment. The considerable improvement obtained with the short term octreotide treatment in patients with primary hypertrophic cardiomyopathy seems promising.